But ultimately,"I think it's hard to build a super-valuable business that changes the industry if you're focused on a single swathe. And that's where 90-plus-percent of the companies are," Gibson said in an interview at Business Insider's New York City headquarters in June.
Recursion has raised $333.7 million total, including the Series C, with a $646 million valuation, according to PitchBook.Creating a new drug takes a decade and costs a fortune. Investors have poured almost $1 billion into startups trying to change that. "Candidly, I think big pharma is asleep behind the wheel" in this area, Dar said. Lux Capital has $1.5 billion under management, and Recursion is"one of our biggest positions across our funds," Dar said.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: